novo nordisk - Search News

Order byBest matchMost fresh

Eli Lilly, Novo Nordisk and Zepbound

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial. The data is the first head-to-head trial comparing the wildly popular medicines,

· 8h

Eli Lilly vs. Novo Nordisk: Which Pharma Stock Is Likely to Do Better in 2025?

· 1d

Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Study

· 23h

First head-to-head trial found Zepbound beats Wegovy for weight loss

In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.

· 1d

New study compares Wegovy and Zepbound for the first time

· 1d

Study finds Zepbound may help people lose more weight than Wegovy

· 1d

Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study

Participants who took Eli Lilly’s tirzepatide, which is sold as Zepbound, lost 50 pounds on average, while those using Novo Nordisk’s semaglutide, also known as Wegovy, lost an average of 33 pounds.

· 1d

Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival’s Wegovy

· 1d

Here’s how much extra weight is lost with Zepbound over Wegovy

12h

Novo Nordisk: A Strategy With High Potential For Volatile Times

Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on NVO stock.

Applied Clinical Trials Online1h

Novo Nordisk’s Sogroya Demonstrates Favorable Outcomes in Phase III Trial for Children’s Growth Disorders

The REAL8 basket study showed Sogroya (somapacitan) was non-inferior to Norditropin (somatropin) in improving yearly growth rate.

6don MSN

Novo Nordisk shares are rising after the company cut its outlook. It’s been that kind of year.

Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But that’s reflective of the tough times the Danish maker of Ozempic and other weight-loss drugs has had.

Novo Nordisk's Sogroya Supports Effective Weekly Alternative To Daily Hormone Therapy Across Three Growth Disorders

Novo Nordisk A/S (NYSE:NVO) on Monday presented data from the phase 3 REAL8 basket study investigating once-weekly Sogroya (somapacitan) in four different but related growth disorder indications, including small for gestational age (SGA),

6don MSN

Novo Nordisk's CFO sceptical Trump executive order on drug manufacturing can cut timelines

Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to reduce the time it takes to approve pharmaceutical plants in the country will significantly change timelines for the pharma industry.

Explore more

6hon MSN

Novo Nordisk A/S (NVO): A Bull Case Theory

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will summarize the bulls’ thesis on NVO.

Currency hedging and new U.S. factories: Novo Nordisk CFO thinks Wegovy maker can outmaneuver global trade wars

Novo Nordisk is hedging and building its way around a global tariff war that may threaten the Wegovy maker’s plans to expand in the U.S. Karsten Munk Knudsen, Novo Nordisk’s chief financial officer, told Fortune the company is well-placed to handle the geopolitical upheaval that rocked global business in March and April.

Novo Nordisk: It's Not Been This Cheap For Many Years

Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why NVO stock is a Buy.

6don MSN

Novo Nordisk hopes to see US Wegovy sales recover soon

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound copycats is enforced this month, its CEO said on Wednesday after the company cut its 2025 forecasts.

Novo Nordisk Reports Positive Results for Growth Disorder Treatment

Novo Nordisk reported positive data from a late-stage trial of its once-weekly Sogroya treatment for children with growth disorders.

6don MSN

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs

Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster weight-loss and diabetes drugs in the U.S. hold back its sales.